Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue.

Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderweyde T, Citro A, Mehta T, Zaarur N, McKee A, Bowser R, Sherman M, Petrucelli L, Wolozin B. · 2010

Read Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. by Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderweyde T, Citro A, Mehta T, Zaarur N, McKee A, Bowser R, Sherman M, Petrucelli L, Wolozin B. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2952586.txt.

Introduction

Liu-Yesucevitz and co-authors studied the protein TDP-43, a main ingredient of the clumps found in many cases of motor neuron disease and a form of dementia, in a 2010 study. The protein normally sits in the nucleus but builds up in the cell body in diseased brain areas.

In cultured cells, stress pushed TDP-43 into clumps that largely overlapped with stress granules, temporary RNA storage bodies. Disease-linked mutant forms clumped more readily and built up in forms that resist dissolving. Binding to granule proteins such as TIA-1, partly through RNA, explains the link and suggests stress handling goes wrong early.

Catalog record

CREATORLiu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderweyde T, Citro A, Mehta T, Zaarur N, McKee A, Bowser R, Sherman M, Petrucelli L, Wolozin B.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE71 KB
LICENSECC0 1.0 Universal
RIGHTSCC0
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2952586

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Tar DNA Binding Protein-43 (TDP-43) Associates with Stress Granules: Analysis of Cultured Cells and Pathological Brain Tissue By Liqun Liu-Yesucevitz, Aylin Bilgutay, Yong-Jie Zhang, Tara Vanderwyde, Allison Citro, Tapan Mehta, Nava Zaarur, Ann McKee, Robert Bowser, Michael Sherman, Leonard Petrucelli, Benjamin Wolozin Published in: PLoS ONE DOI: 10.1371/journal.pone.0013250 ABSTRACT Abstract Tar DNA Binding Protein-43 (TDP-43) is a principle component of inclusions in many cases of frontotemporal lobar degeneration (FTLD-U) and amyotrophic lateral sclerosis (ALS). TDP-43 resides predominantly in the nucleus, but in affected areas of ALS and FTLD-U central nervous system, TDP-43 is aberrantly processed and forms cytoplasmic inclusions. The mechanisms governing TDP-43 inclusion formation are poorly understood. Increasing evidence indicates that TDP-43 regulates mRNA metabolism by interacting with mRNA binding proteins that are known to associate with RNA granules. Here we show that TDP-43 can be induced to form inclusions in cell culture and that most TDP-43 inclusions co-localize with SGs. SGs are cytoplasmic RNA granules that consist of mixed protein - RNA complexes. Under stressful conditions SGs are generated by the reversible aggregation of prion-like proteins, such as TIA-1, to regulate mRNA metabolism and protein translation. We also show that disease-linked mutations in TDP-43 increased TDP-43 inclusion formation in response to stressful stimuli. Biochemical studies demonstrated that the increased TDP-43 inclusion formation is associated with accumulation of TDP-43 detergent insoluble complexes. TDP-43 associates with SG by interacting with SG proteins, such as TIA-1, via direct protein-protein interactions, as well as RNA-dependent interactions. The signaling pathway that regulates SGs formation also modulates TDP-43 inclusion formation. We observed that inclusion formation mediated by WT or mutant TDP-43 can be suppressed by treatment with translational inhibitors that suppress or reverse SG formation. Finally, using Sudan black to quench endogenous autofluorescence, we also demonstrate that TDP-43 positive-inclusions in pathological CNS tissue co-localize with multiple protein markers of stress granules, including TIA-1 and eIF3. These data provide support for accumulating evidence that TDP-43 participates in the SG pathway. INTRODUCTION TDP-43 is the principle protein component of inclusions in ALS and ubiquitin positive frontotemporal lobar degeneration (FTLD-U) [1]. Currently more than thirty mutations in TDP-43 have been identified in familial and sporadic ALS [2], [3]. Mutations in TDP-43 are considered as a major cause of familial ALS. TDP-43 is a 414 amino acid nuclear protein encoded by the TARDBP gene on chromosome 1. Although it is ubiquitously expressed in all tissues, it highly expresses in the brain and kidney [4]. TDP-43 is an mRNA binding protein that plays important functions in regulating mRNA metabolism involved in several functions, including transcriptional repression, exon skipping and RNA splicing [5], [6]. It contains two RNA binding domains and a glycine rich domain at the C terminus. The two RNA recognition motifs and the C terminal glycine-rich domains in the TAR-DNA appear to be important for its interactions with nucleic acids [5], [6]. TDP-43 predominantly expresses in the nucleus where it exerts its biological functions, but in pathological tissue TDP-43 is aberrantly processed and forms inclusions in the cytoplasm. The mislocalization of TDP-43 in the cytoplasm highlights important gaps in our knowledge of TDP-43 biology. mRNA binding proteins facilitate mRNA trafficking from the nucleus to the cytoplasm as part of the biological machinery that regulates mRNA metabolism, such as RNA decay and protein translation. RNA decay is a constitutive process that occurs in cytoplasmic compartments termed processing bodies (P-bodies). However, under stressful conditions mRNA binding proteins consolidate mRNA in cytoplasmic compartments, termed the stress granules (SGs); this recruitment is mediated by multiple proteins, including T-cell intracellular antigen 1 (TIA-1), RasGAP-associated endoribnuclease (G3BP), elongation initiation factor 3 (eIF3) and poly-A binding protein (PABP) [7]. SGs function in part to triage RNA and sequester transcripts not needed for coping with the stress [7]. The mechanism of SG formation is striking because it results from the regulated, reversible aggregation process of mRNA binding proteins with prion-like domains, such as TIA-1, TIAR and G3BP[8]. TDP-43 inclusions isolated from brains of subjects with FTLD-U contain full-length TDP-43 as well as C-terminal cleavage fragments that are approximately 25 and 35 KD in size [1]. Recent studies with cell lines indicate that TDP-43 can form cytoplasmic inclusions when expression is forced to the cytoplasm by removal of the nuclear localization signal [9], [10]. TDP-43 inclusions also occur upon apoptosis, possibly because the caspase-generated cleavage fragments of TDP-43 have a strong tendency to aggregate [9], [11], [12], [13]. Increasing evidence suggests that TDP-43 cytoplasmic inclusions observed in cell culture are SGs [14], [15], but the mechanisms by which TDP-43 might associate with SG are unknown. In addition, also unknown are questions such as whether SG biology contributes to ALS and how disease-linked TDP-43 mutations might participate in this process. We now report that TDP-43 co-localizes with SGs in cells and in affected CNS tissue from patients with ALS or FTLD-U. We also report that TDP-43 binds to TIA-1, an intrinsic SG protein, which provides a potential mechanism for association of TDP-43 with SGs in ALS and FTLD-U. In additions, we report that disease-linked mutations in TDP-43 increase the formation of cytoplasmic TDP-43 inclusions that are co-localized with SG markers. RESULTS Over-expressed TDP-43 forms cytoplasmic inclusions that co-localize with SG To test whether inclusions would form in neuronal cells, human BE-M17 neuroblastoma cells were transfected with WT TDP-43, TDP-4386–414 or TDP-43216–414 constructs N-terminally tagged with EGFP (Fig 1). The TDP-4386–414 and TDP-43216–414 deletion constructs were designed to correlate with the TDP-43 cleavage fragments of approximately 35 and 25 KD that are present in brain of subjects with TDP-43 pathology [1], [11]. Full length WT TDP-43 predominently localized to the nucleus under basal conditions with only 10% of the cells exhibiting TDP-43 inclusions (Fig. 2A; Supplemental figure S1 shows an example of a cell with some cytoplasmic TDP-43 inclusions). In contrast, about 30% of the cells over-expressing TDP-4386-414formed abundant cytoplasmic inclusions under basal conditions (Fig. 2A). Cells expressing the TDP-43216–414 construct also formed inclusions (Fig. 2A), but the number of cells exhibiting fluorescence was low, possibly due to cytotoxicity [11]. The inclusions were predominantly cytoplasmic, but were also present in the nucleus (Fig. 2A). [Figure: TDP-43 constructs: Diagram showing the TDP-43 constructs used in this report.EGFP, Enhanced Green Fluorescent Protein; RRM, RNA recognition motif; GRR, Glycine rich domain; NLS, nuclear localization signal; NES, nuclear export signal.] [Figure: TDP-43 inclusions co-localize with SG proteins.A.) Cellular distribution of TDP-43::EGFP constructs in human neuroblastoma BE-M17 cells under basal conditions and after treatment with arsenite; the cells are co-labeled with anti-TIA-1 antibody (red, labeling SGs) and with DAPI (blue, labeling nuclei). Basal conditions (left panel): WT TDP-43 (T-FL) typically shows diffuse nuclear expression, while TDP-43216–414 (T-216) and TDP-4386–414 (T-86)::EGFP constructs form cytoplasmic and nuclear inclusions. TDP-43 reactivity co-localizes with RNA binding protein, TIA-1. Arsenite treatment (right panel): Treatment with arsenite (0.5 mM, 1 hr) induces some TDP-43::EGFP to translocate to the cytoplasm where it forms inclusions (arrows) that co-localize with TIA-1, indicating that the inclusions are SGs. The TDP-43216–414 and TDP-4386–414::EGFP constructs form inclusions in the cytoplasm (arrows) and nucleus, but only inclusions generated by the TDP-4386–414 construct are increased by arsenite. The inclusions present in arsenite treated cells co-localize with TIA-1. B.) Quantification of TDP-43 inclusions that co-localize with TDP-43 and

Read the complete text